Literature DB >> 7192151

Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy.

D S Thompson, N Naqvi, S M Juul, R H Swanton, D J Coltart, B S Jenkins, M M Webb-Peploe.   

Abstract

Myocardial substrate extraction, coronary sinus flow, cardiac output, and left ventricular pressure were measured at increasing pacing rates before and after propranolol (0.2 mg/kg) in 13 patients with hypertrophic obstructive cardiomyopathy (HOCM) during diagnostic cardiac catheterisation. At the lowest pacing rate myocardial oxygen consumption varied considerably between patients and very high values were found in several individuals (range 10.1 to 57.5 ml/min). These large differences between patients were not explicable by differences in cardiac work; consequently, cardiac efficiency, estimated from the oxygen cost of external work, varied between patients and was lower than normal in all but two. The pattern of substrate extraction at the lowest pacing rate was similar to results reported for the normal heart, and measured oxygen consumption could be accounted for by complete oxidation of the substrates extracted; thus there was no evidence of a gross abnormality of oxidative metabolism, suggesting that low efficiency lay in the utilisation rather than in the production of energy. Each of the four patients with the highest myocardial oxygen consumption and lowest values of efficiency sustained progressive reductions in lactate and pyruvate extraction as heart rate increased, and at the highest pacing rate had low (< 3%) or negative lactate extraction ratios. In three of these four, coronary sinus flow did not increase progressively with each increment in heart rate. One patient with low oxygen consumption and normal efficiency also failed to increase coronary flow with the final increment in heart rate, and produced lactate at the highest pacing rate. Thus the five patients in whom pacing provoked biochemical evidence of ischaemia all had excessive myocardial oxygen demand and/or limited capacity to increase coronary flow. Propranolol did not change lactate extraction significantly at any pacing rate in either the ischaemic or non-ischaemic groups. In only one patient was ischaemia at the highest pacing rate abolished after propranolol, and this was associated with a 30 per cent reduction in oxygen consumption. These results do not demonstrate a direct effect of propranolol upon myocardial metabolism in patients with HOCM, but emphasise the potential value of beta-blockade in protecting these patients from excessive increases in heart rate.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7192151      PMCID: PMC482433          DOI: 10.1136/hrt.44.5.488

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  39 in total

1.  Mechanisms of angina in aortic stenosis.

Authors:  E L Fallen; W C Elliott; R Gorlin
Journal:  Circulation       Date:  1967-10       Impact factor: 29.690

Review 2.  Hemodynamic aspects of heart failure.

Authors:  H T Dodge; W A Baxley
Journal:  Am J Cardiol       Date:  1968-07       Impact factor: 2.778

3.  Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol.

Authors:  M D Flamm; D C Harrison; E W Hancock
Journal:  Circulation       Date:  1968-11       Impact factor: 29.690

4.  Analysis of left ventricular function by atrial pacing.

Authors:  J O Parker; F Khaja; R B Case
Journal:  Circulation       Date:  1971-02       Impact factor: 29.690

5.  Regional venous drainage of the human heart.

Authors:  W B Hood
Journal:  Br Heart J       Date:  1968-01

6.  Hemodynamic accompaniments of angina: a comparison during angina induced by exercise and by atrial pacing.

Authors:  K P O'Brien; L M Higgs; D L Glancy; S E Epstein
Journal:  Circulation       Date:  1969-06       Impact factor: 29.690

7.  Left heart hemodynamics during angina pectoris induced by atrial pacing.

Authors:  J W Linhart; F J Hildner; S S Barold; P Samet
Journal:  Circulation       Date:  1969-10       Impact factor: 29.690

8.  Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade.

Authors:  L S Cohen; E Braunwald
Journal:  Circulation       Date:  1967-05       Impact factor: 29.690

9.  Propranolol in management of muscular subaortic stenosis.

Authors:  G Sloman
Journal:  Br Heart J       Date:  1967-09

10.  Propranolol and angina pectoris.

Authors:  S Wolfson; R A Heinle; M V Herman; H G Kemp; J M Sullivan; R Gorlin
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

View more
  15 in total

1.  An equation to predict the changes in peak left ventricular pressure in hypertrophic obstructive cardiomyopathy after treatment: application to the administration of disopyramide.

Authors:  K Niki; M Sugawara; S Tanino; K Iwade; S Hosoda; H Kasanuki
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

Review 2.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

Review 3.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

4.  Estimation of time constant of left ventricular relaxation.

Authors:  D S Thompson; C B Waldron; D J Coltart; B S Jenkins; M M Webb-Peploe
Journal:  Br Heart J       Date:  1983-03

5.  Cardiac work and myocardial substrate extraction in congestive cardiomyopathy.

Authors:  D S Thompson; N Naqvi; S M Juul; R H Swanton; P Wilmshurst; D J Coltart; B S Jenkins; M M Webb-Peploe
Journal:  Br Heart J       Date:  1982-02

6.  Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy.

Authors:  M Shimizu; N Sugihara; Y Kita; K Shimizu; Y Horita; K Nakajima; J Taki; R Takeda
Journal:  Br Heart J       Date:  1992-02

7.  Pressure-derived indices of left ventricular isovolumic relaxation in patients with hypertrophic cardiomyopathy.

Authors:  D S Thompson; P Wilmshurst; S M Juul; C B Waldron; B S Jenkins; D J Coltart; M M Webb-Peploe
Journal:  Br Heart J       Date:  1983-03

8.  Shortening baroreflex delay in hypertrophic cardiomyopathy patients -- an unknown effect of β-blockers.

Authors:  Agnieszka Katarzynska-Szymanska; Romuald Ochotny; Zofia Oko-Sarnowska; Hanna Wachowiak-Baszynska; Tomasz Krauze; Jaroslaw Piskorski; Adrian Gwizdala; Przemyslaw Mitkowski; Przemyslaw Guzik
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

9.  Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy.

Authors:  Stefan A J Timmer; Tjeerd Germans; Marco J W Götte; Iris K Rüssel; Pieter A Dijkmans; Mark Lubberink; Jurrien M ten Berg; Folkert J ten Cate; Adriaan A Lammertsma; Paul Knaapen; Albert C van Rossum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

10.  Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.

Authors:  Shintaro Haruki; Yuichiro Minami; Atsushi Suzuki; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2014-06-12       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.